This acquisition brings together two complementary strengths—the industry-leading Illumina sequencing ecosystem and advanced SomaLogic proteomics technology to deliver more powerful, integrated solutions for customers. By combining our capabilities, we will accelerate innovation across multiomics, expand the tools available for biomarker discovery and disease profiling, and enhance the overall value and performance of our shared product portfolio.

Yes. Your current pricing, contract terms, and conditions will remain the same. SomaLogic and Illumina will continue operating as they do today, and any future changes will be evaluated carefully and communicated well in advance so you have full visibility and continuity in your service experience.

You can visit the Illumina Products page or the SomaLogic site to learn more about each product portfolio.

If you have additional questions, you can continue reaching out to the same sales and support contacts you use today or utilize the additional contacts listed further below.